Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JANX013
- Development stage
- Preclinical
- Lead developer
- Janux Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JANX013 is a CD28 co-stimulatory Tumor Activated Immunomodulator (TRACIr) being developed by Janux Therapeutics for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is designed as a PSMA-targeted biologic immunotherapy that utilizes a proprietary tumor-activated technology platform to stimulate the immune system through CD28 co-stimulation specifically within the tumor microenvironment. This mechanism is intended to enhance anti-tumor activity while minimizing systemic safety issues typically associated with CD28 activation. JANX013 is planned for clinical development in combination with JANX007, a PSMA-targeted T-cell engager, to provide a synergistic immune response against prostate cancer cells.
- Other names
- PSMAxCD28-TRACIrPSMAxCD-28-TRACIrPSMAxCD 28-TRACIrPSMA-TRACIr
02
Targets
PSMA (Prostate-specific membrane antigen)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on JANX013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JANX013.